General Electric Co.'s biopharma business accounted for 60% of the almost $5 billion in revenue from the company's life-sciences segment last year. "GE Pitches Investors on Its Health-Care Unit, a Steady Source of Cash," at 8 a.m. ET, incorrectly stated in the ninth paragraph that the biopharma business accounted for 75% of the segment's $4 billion in revenue. (Dec. 1, 2019)


(END) Dow Jones Newswires

December 01, 2019 14:02 ET (19:02 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.